<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02572024</url>
  </required_header>
  <id_info>
    <org_study_id>BATstudy</org_study_id>
    <nct_id>NCT02572024</nct_id>
  </id_info>
  <brief_title>The Effect of Baroreflex Activation Therapy (BAT) on Blood Pressure and Sympathetic Function in Patients With Resistant Hypertension (The Nordic BAT Study)</brief_title>
  <acronym>The Nordic BAT</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Helsinki</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <brief_summary>
    <textblock>
      Resistant hypertension (RH) affects some 10% to 15% of all patients with hypertension. These&#xD;
      patients are at a clearly increased risk for end organ damage and mortality. Furthermore,&#xD;
      arterial hypertension is a multifactorial disease including genetic, lifestyle, dietary,&#xD;
      metabolic, and sympathetic factors. However, the current treatment modalities have not been&#xD;
      optimal in targeting the compensatory changes in sympathetic nervous system function and new&#xD;
      strategies have been warranted.&#xD;
&#xD;
      Baroreflex activation therapy (BAT) is a special treatment option for some patients with RH&#xD;
      that modulates the autonomic nervous system to restore sympathovagal balance. Notably, in BAT&#xD;
      both long-term safety and efficacy in a large-scale, randomized, double blind, controlled&#xD;
      trial has been shown. However, the trial design and BAT methodology resulted in that the&#xD;
      first generation Rheos® system did not achieve the prespecified endpoints for short-term&#xD;
      safety and efficacy.&#xD;
&#xD;
      Notably, a second-generation minimally invasive BAT system (Barostim Neo®) has now been&#xD;
      developed to address these limitations although randomized, double blind, controlled clinical&#xD;
      trials are still lacking. Noteworthy, in the recent European Society of Hypertension/European&#xD;
      Society of Cardiology (ESH/ESC) Guidelines for the management of arterial hypertension,&#xD;
      carotid baroreceptor stimulation is mentioned as one of the options to treat resistant&#xD;
      hypertension.&#xD;
&#xD;
      Based on these data the aim of this randomized, double-blind, parallel-design clinical trial&#xD;
      is to examine the effect of BAT compared to continuous pharmacotherapy on blood pressure, as&#xD;
      well as arterial and cardiac function and structure using non-invasive high technology&#xD;
      methodology, in a Nordic multicentre study.&#xD;
&#xD;
      This study will include 100 patients with RH (20 from Helsinki). Eligible patients are&#xD;
      between 18 and 70 years and have a daytime systolic ambulatory blood pressure 145 mmHg or&#xD;
      more, and/or a daytime diastolic ambulatory blood pressure of 95 mmHg or more, after&#xD;
      witnessed intake of antihypertensive treatment (including at least 3 antihypertensive drugs&#xD;
      preferably including a diuretic), with no changes in medication for a minimum of 4 weeks&#xD;
      prior to enrolment. Patients with severe renal insufficiency, type 1 diabetes, psychiatric&#xD;
      illness, severe cardiovascular disease, or any complication that is a risk to the planned&#xD;
      surgery are exclusion criteria.&#xD;
&#xD;
      The primary end point is to test whether BAT reduces 24-hour systolic ambulatory blood&#xD;
      pressure at 8 months of follow-up compared to continuous pharmacotherapy. Secondary end&#xD;
      points are to test whether BAT reduces home blood pressure during follow-up compared to&#xD;
      continuous pharmacotherapy, whether BAT reduces office blood pressure during follow-up&#xD;
      compared to continuous pharmacotherapy, and the effect of BAT on autonomic function measured&#xD;
      as eg. baroreflex sensitivity and heart rate variability.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">April 2028</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in systolic ambulatory blood pressure in response to BAT therapy</measure>
    <time_frame>8 months</time_frame>
    <description>Unit: mmHg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in systolic ambulatory blood pressure in response to BAT therapy</measure>
    <time_frame>19 months</time_frame>
    <description>Unit: mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in home/office blood pressure in response to BAT therapy</measure>
    <time_frame>19 months</time_frame>
    <description>Unit: mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in autonomic function in response to BAT therapy</measure>
    <time_frame>19 months</time_frame>
    <description>Unit: ms/mmHg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Resistant Hypertension</condition>
  <arm_group>
    <arm_group_label>Baroreflex activation therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BAT ON</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>BAT OFF</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BAT</intervention_name>
    <description>Baroreflex activation therapy device ON</description>
    <arm_group_label>Baroreflex activation therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Baroreflex activation therapy device OFF</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eligible patients have a daytime systolic ambulatory blood pressure 145 mmHg or more,&#xD;
             and/or a daytime diastolic ambulatory blood pressure of 95 mmHg or more, after&#xD;
             witnessed intake of antihypertensive treatment (including at least 3 antihypertensive&#xD;
             drugs preferably including a diuretic), with no changes in medication for a minimum of&#xD;
             4 weeks prior to enrolment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with secondary causes of hypertension will be excluded.&#xD;
&#xD;
          -  Further exclusion criteria are renal insufficiency with an estimated glomerular&#xD;
             filtration rate ≤30 ml/min/1.73 m2 (using the Chronic Kidney Disease Epidemiology&#xD;
             [CKD-EPI] formula), untreated sleep apnoea, pregnancy, type 1 diabetes, alcohol or&#xD;
             substance abuse or psychiatric illnesses, other heart rhythm than sinus (well&#xD;
             controlled atrial fibrillation is not a contraindication), uncontrolled systolic heart&#xD;
             failure (or an ejection fraction of less than 40% in echocardiography), aortic&#xD;
             stenosis (mean gradient more than 25 mmHg in echocardiography).&#xD;
&#xD;
          -  Myocardial infarction, hypertensive crisis, symptomatic orthostatic hypotension,&#xD;
             unstable angina, syncope, or cerebral vascular accident within the 3 months before&#xD;
             enrolment will also be exclusion criteria.&#xD;
&#xD;
          -  Furthermore, known or suspected baroreflex failure or autonomic neuropathy, carotid&#xD;
             artery stenosis as well as prior surgery, radiation, or endovascular stent placement&#xD;
             in the carotid sinus region on both sides, as well as any complication that is a risk&#xD;
             to the planned surgery are exclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daniel Gordin, MD DMSc</last_name>
    <phone>+35894711</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ilkka Tikkanen, Prof</last_name>
    <phone>+35894711</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Hecht Olsen, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Gordin, MD DMSc</last_name>
      <phone>+35894711</phone>
    </contact>
    <contact_backup>
      <last_name>Ilkka Tikkanen, MD DMSc</last_name>
      <phone>+35894711</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Oslo</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fadl Elmula, MD DMSc</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital, Sweden</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bert Andersson, MD DMScl</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anders Gottsäter, MD DMSc</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 7, 2015</study_first_submitted>
  <study_first_submitted_qc>October 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2015</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Daniel Gordin</investigator_full_name>
    <investigator_title>MD DMSc</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

